Artículos de revistas
A Cross-sectional Study Of The Forearm Bone Mineral Density In Long-term Current Users Of The Injectable Contraceptive Depot Medroxyprogesterone Acetate
Contraception. , v. 84, n. 5, p. e31 - e37, 2011.
Background: One of the well-established effects of the use of depot medroxyprogesterone acetate (DMPA) contraception is on bone mineral density (BMD). However, little evidence assesses the skeletal impact of long-term DMPA use. The objective of this study was to assess BMD on a cohort of women who used DMPA uninterruptedly between 1 and 15 years. Study Design: A cross-sectional study with 232 users of DMPA matched to a group of 232 copper intrauterine device (IUD) users by age (±1) (range 20-53 and 20-51 years for DMPA and IUD group, respectively), body mass index (BMI; kg/m 2) (±1) (range 17.4-44.5 and 18.5-40.2 for DMPA and IUD group, respectively) and years of use (1-15 years) was performed. The women underwent forearm BMD evaluation using dual-energy X-ray absorptiometry. The women were divided into five groups (1-5) according to the length of DMPA use: 1-3, 4-6, 7-9, 10-12 and 13-15 years of use. Results: The mean (±SEM) age was 38.3±0.5 and 38.1±0.57 years and the mean (±SEM) BMI (kg/m 2) was 26.4±0.3 and 26.3±0.3 for the entire group of women in the DMPA and IUD group, respectively. Women who used DMPA or IUD for a short time were younger and had lower BMI (kg/m 2) than the women who used either contraceptive method long term. White women were significantly more frequent among IUD users (p<.040) than DMPA users. In addition, parity (p<.053) and physical activity (p<.012) were significantly greater among IUD users, whereas the prevalence of washing clothes by hand (p<.025) was significantly greater among DMPA users. There was no significant difference in BMD measurements between the current users of DMPA and those who had used the IUD either at the distal or ultra-distal sections of the forearm. However, women who had used DMPA for 13-15 years showed significantly lower BMD at the distal and ultra-distal radius when compared to IUD users (p<.041 and.042, respectively). Otherwise, all other differences in BMD values between DMPA and IUD users were nonsignificant at the distal and ultra-distal radius. For both DMPA and IUD users, we noted a direct correlation between higher BMD and BMI (kg/m 2) and an inverse correlation between BMD and age for distal and ultra-distal radius. Conclusions: Our study did not detect a deleterious effect on measurements of forearm BMD among long-term DMPA users with less than 13 years of use; however, a significantly lower BMD was observed at 13-15 years of use in DMPA users when compared to IUD users. Bone mineral density was inversely correlated to older age and directly correlated to BMI (kg/m 2). © 2011 Elsevier Inc. All rights reserved.845e31e37Westhoff, C., Depot-medroxyprogesterone acetate injection (Depo-Provera®): A highly effective contraceptive option with proven long-term safety (2003) Contraception, 68 (2), pp. 75-87. , DOI 10.1016/S0010-7824(03)00136-7Fraser, I.S., Weisberg, E., A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate (1981) Med J Aust, 1 (SUPPL 1), pp. 3-19Kaunitz, A.M., Current concepts regarding use of DMPA (2002) J Reprod Med, 47 (9 SUPPL), pp. 785-789Bahamondes, L., Trevisan, M., Andrade, L., The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera (2000) Contraception, 62, pp. 23-27Bagger, Y.Z., Tanko, L.B., Alexandersen, P., Hansen, H.B., Mollgaard, A., Ravn, P., Qvist, P., Christiansen, C., Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: The PERF study (2004) Bone, 34 (4), pp. 728-735. , DOI 10.1016/j.bone.2003.12.021, PII S8756328203004794Renner, R.M., Edelman, A.B., Kaunitz, A.M., Depot medroxyprogesterone acetate contraceptive injections and skeletal health (2010) Womens Health (Lond Engl), 6, pp. 339-342D'Arcangues, C., WHO statement on hormonal contraception and bone health (2006) Contraception, 73, pp. 443-444Black Box Warning on Depo-Provera Contraceptive Injection, , United States Food and Drug Administration November 17, 2004Duff, G., Committee on Safety of Medicines Updated Prescribing Advice on the Effect of Depo-Provera Contraception on Bones, , http://www.mhra.gov.uk, HSS (MD) 39-2004. Letter to healthcare professionals. November 18, 2004. Accessed October 9, 2010http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/medeff/ depo-provera_pa_ap-eng.pdf, Acessed November 10, 2011http://www.familypact.org/_Resources/Documents/CPA_Depo- Provera_and_Bone_Density_Aug_2005, Office of Family Planning, California Department of Health Services. Family PACT Clinical Practice Alert. Accessed June 22, 2011American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects (2008) Obstet Gynecol, 112, pp. 727-730Guilbert, E.R., Brown, J.P., Kaunitz, A.M., The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health (2009) Contraception, 79, pp. 167-177Kaunitz, A.M., Depo-Provera's black box: Time to reconsider? (2005) Contraception, 72 (3), pp. 165-167. , DOI 10.1016/j.contraception.2005.05.011, PII S0010782405002210Sanches, L., Marchi, N.M., Castro, S., Julianato, C.T., Villarroel, M., Bahamondes, L., Forearm bone mineral density in postmenopausal former user of depot medroxyprogesterone acetate (2008) Contraception, 78, pp. 365-369. , Erratum in: Contraception. 2009;79:159-60Viola, A.S., Castro, S., Marchi, N.M., Bahamondes, M.V., Viola, C.F.M., Bahamondes, L., Long-term assessment of forearm bone mineral density in postmenopausal former users of depot medroxyprogesterone acetate (2011) Contraception, 84, pp. 122-127Beksinska, M.E., Kleinschmidt, I., Smit, J.A., Farley, T.M., Bone mineral density in a cohort of adolescents during use of norethisterone enanthate, depot-medroxyprogesterone acetate or combined oral contraceptives and after discontinuation of norethisterone enanthate (2009) Contraception, 79, pp. 345-349Perrotti, M., Bahamondes, L., Petta, C., Castro, S., Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate (2001) Fertil Steril, 76, pp. 469-473Jones, T., Davie, M.W., Bone mineral density at distal forearm can identify patients with osteoporosis at spine or femoral neck (1998) Br J Rheumatol, 37, pp. 539-543Marshall, D., Johnell, O., Wedel, H., Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures (1996) British Medical Journal, 312 (7041), pp. 1254-1259Picard, D., Brown, J.P., Rosenthall, L., Couturier, M., Levesque, J., Dumont, M., Ste-Marie, L.-G., Dodin, S., Ability of Peripheral DXA Measurement to Diagnose Osteoporosis As Assessed by Central DXA Measurement (2004) Journal of Clinical Densitometry, 7 (1), pp. 111-118. , DOI 10.1385/JCD:7:1:111Cundy, T., Cornish, J., Roberts, H., Reid, I.R., Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception (2002) Am J Obstet Gynecol, 186, pp. 978-983Orr-Walker, B.J., Evans, M.C., Ames, R.W., Clearwater, J.M., Cundy, T., Reid, I.R., The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post- menopausal women (1998) Clinical Endocrinology, 49 (5), pp. 615-618. , DOI 10.1046/j.1365-2265.1998.00582.xLappe, J.M., Stegman, M.R., Recker, R.R., The impact of lifestyle factors on stress fractures in female army recruits (2001) Osteoporosis International, 12 (1), pp. 35-42. , DOI 10.1007/s001980170155Watson, K.C., Lentz, M.J., Cain, K.C., Associations between fracture incidence and use of depot medroxyprogesterone acetate and anti-epileptic drugs in women with developmental disabilities (2006) Women's Health Issues, 16 (6), pp. 346-352. , DOI 10.1016/j.whi.2006.09.003, PII S1049386706001125Vestergaard, P., Rejnmark, L., Mosekilde, L., The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women (2008) Contraception, 78, pp. 459-464Meier, C., Brauchli, Y.B., Jick, S.S., Kraenzlin, M.E., Meier, C.R., Use of depot medroxyprogesterone acetate and fracture risk (2010) J Clin Endocrin Metab, 95, pp. 4909-4916Kaunitz, A.M., Grimes, D.A., Removing the black box warning for depot medroxyprogesterone acetate (2011) Contraception, 84, pp. 212-213Tang, O.S., Tang, G., Yip, P.S.F., Li, B., Further evaluation on long-term depot-medroxyprogesterone acetate use and bone mineral density: A longitudinal cohort study (2000) Contraception, 62 (4), pp. 161-164. , DOI 10.1016/S0010-7824(00)00168-2, PII S0010782400001682Berenson, A.B., Breitkopf, C.R., Grady, J.J., Rickert, V.I., Thomas, A., Effects of hormonal contraception on bone mineral density after 24 months of use (2004) Obstetrics and Gynecology, 103 (5), pp. 899-906. , DOI 10.1097/01.AOG.0000117082.49490.d5Scholes, D., Lacroix, A.Z., Ichikawa, L.E., Barlow, W.E., Ott, S.M., Injectable hormone contraception and bone density: Results from a prospective study (2002) Epidemiology, 13, pp. 581-587Kaunitz, A.M., Miller, P.D., Rice, V.M., Ross, D., McClung, M.R., Bone mineral density in women aged 25-35 years receiving depot medroxyprogesterone acetate: Recovery following discontinuation (2006) Contraception, 74 (2), pp. 90-99. , DOI 10.1016/j.contraception.2006.03.010, PII S0010782406000898Scholes, D., LaCroix, A.Z., Ichikawa, L.E., Barlow, W.E., Ott, S.M., Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception (2005) Archives of Pediatrics and Adolescent Medicine, 159 (2), pp. 139-144. , DOI 10.1001/archpedi.159.2.139Harel, Z., Johnson, C.C., Gold, M.A., Recovery of bone mineral density in adolescents following the use of depot medroxyprogesterone acetate contraceptive injections (2010) Contraception, 81, pp. 281-291Gai, L., Zhang, J., Zhang, H., Gai, P., Zhou, L., Liu, Y., The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age (2011) Contraception, 83, pp. 218-222Gbolade, B., Ellis, S., Murby, B., Randall, S., Kirkman, R., Bone density in long term users of depot medroxyprogesterone acetate (1998) British Journal of Obstetrics and Gynaecology, 105 (7), pp. 790-794Bonny, A.E., Secic, M., Cromer, B.A., Relationship between weight and bone mineral density in adolescents on hormonal contraception (2011) J Pediatr Adolesc Gynecol, 24, pp. 35-38Kaunitz, A.M., Harel, Z., Bone, H., Retrospective cohort study of DMPA and fractures in reproductive age women (2010) Presented at Association of Reproductive Health Professional Annual Meeting, Atlanta, GAPaschall, S., Kaunitz, A.M., Depo-Provera and skeletal health: A survey of Florida obstetrics and gynecologist physicians (2008) Contraception, 78, pp. 370-376